On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

420 with CNW — Case Report Shows CBD Oil Used with Other Medications Could Help Individuals Living with Batten Disease

A case report proposes that adding cannabis oil to conventional anti-seizure medications may be an effectual way to manage life-threatening seizures caused by status epilepticus that may need urgent medical treatment.

These findings support other reports and growing evidence that call attention to the anti-seizure effects that marijuana-based compounds possess. The study researchers note that despite their findings, additional research is still required to confirm the efficacy and safety of cannabis oil for epilepticus, in addition to decreasing overall seizures in patients. The study was reported in the “Journal of Neurology Research.

In pediatric neurodegenerative disorders, the most prevalent group is neuronal ceroid lipofuscinosis. The disorders, which are also referred to as Batten disease, are caused by mutations in about 14 different genes and are divided into different types. Among all types of Batten disease, seizures are common. Status epilepticus is defined as seizures that occur successively without any separation by consciousness or seizures that last more than five minutes.

If seizures recur after withdrawal or continue for about a day even after administering anesthesia, this is referred to as super-refractory status epilepticus. Both such statuses require urgent medical attention and are life threatening.

While anti-seizure medications work, they aren’t always effective. Growing evidence showed that cannabis oil and other marijuana-based agents may help reduce the frequency of seizures. Many studies associate these benefits with CBD (cannabidiol), which is a nonpsychoactive active component found in cannabis. CBD has been found to have immunomodulatory, anti-inflammatory, neuroprotective, antioxidant and anti-seizure properties.

The first cannabis-based medicine approved in Europe and the United States to treat childhood epilepsies was Epidiolex. The medicine is an oral form of cannabidiol that has been purified. It targets two severe epilepsies: Dravet syndrome and Lennox-Gastaut syndrome. Despite this approval, however, no marijuana-based compounds have been authorized for neuronal ceroid lipofuscinosis.

University of Nicosia Medical School researchers provided a detailed outline of the case of a 25-year-old man who had CLN6 Batten disease. The individual’s seizures began at age 10 and became treatment resistant with age, leading to the use of various anti-seizure medications in different combinations. The medications included piracetam, lacosamide, lamotrigine and levetiracetam.

The man began a trial for cannabis oil that was taken in addition to anti-seizure medication. A significant reduction in seizures was experienced two weeks into the trial with results showing that eight months after the anesthesia medication had been completely withdrawn, the individual had stopped using both zonisamide and clobazam and had experienced a significant reduction in the frequency of seizures.

It should be noted that CBD has not been approved to treat seizures and more studies are needed to not only define a recommended ratio of THC/CBD but also test the safety and effectiveness of cannabis oil.

As CBD and other cannabis compounds gain more recognition for their potential therapeutic benefits, many companies are finding ways to deliver cannabis and other medicines. For example, RYAH Group Inc. is leading the way in finding AI-powered ways to measure the doses of medicine that patients take.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722